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Introduction: Sepsis and septic shock are leading causes of intensive care unit (ICU) mortality. They are
characterized by excessive inflammation, upregulation of procoagulant proteins and depletion of natural
anticoagulants. Plasma exchange has the potential to improve survival in sepsis by removing inflammatory
cytokines and restoring deficient plasma proteins. The objective of this study is to evaluate the efficacy and safety
of plasma exchange in patients with sepsis.
Methods: We searched MEDLINE, EMBASE, CENTRAL, Scopus, reference lists of relevant articles, and grey literature
for relevant citations. We included randomized controlled trials comparing plasma exchange or plasma filtration
with usual care in critically ill patients with sepsis or septic shock. Two reviewers independently identified trials,
extracted trial-level data and performed risk of bias assessments using the Cochrane Risk of Bias tool. The primary
outcome was all-cause mortality reported at longest follow-up. Meta-analysis was performed using a random-effects
model.
Results: Of 1,957 records identified, we included four unique trials enrolling a total of 194 patients (one enrolling
adults only, two enrolling children only, one enrolling adults and children). The mean age of adult patients ranged
from 38 to 53 years (n = 128) and the mean age of children ranged from 0.9 to 18 years (n = 66). All trials were at
unclear to high risk of bias. The use of plasma exchange was not associated with a significant reduction in all-cause
mortality (risk ratio (RR) 0.83, 95% confidence interval (CI) 0.45 to 1.52, I2 60%). In adults, plasma exchange was
associated with reduced mortality (RR 0.63, 95% CI 0.42 to 0.96; I2 0%), but was not in children (RR 0.96, 95% CI 0.28
to 3.38; I2 60%). None of the trials reported ICU or hospital lengths of stay. Only one trial reported adverse events
associated with plasma exchange including six episodes of hypotension and one allergic reaction to fresh frozen
plasma.
Conclusions: Insufficient evidence exists to recommend plasma exchange as an adjunctive therapy for patients
with sepsis or septic shock. Rigorous randomized controlled trials evaluating clinically relevant patient-centered
outcomes are required to evaluate the impact of plasma exchange in this condition.* Correspondence: rzarychanski@cancercare.mb.ca
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Severe sepsis and septic shock are among the leading
causes of death in patients admitted to an ICU world-
wide and, despite advances in treatment and supportive
care, the mortality remains greater than 20% [1-4].
Plasma exchange or plasma filtration involves the sep-
aration of plasma from whole blood, removal of the
plasma, and replacement with normal saline, albumin, or
fresh frozen plasma [5,6]. Plasma exchange has the po-
tential to improve survival in sepsis by restoring homeo-
stasis through the removal of harmful substances (for
example, bacterial toxins, activated complement and co-
agulation factors and inflammatory cytokines) and, when
the replacement fluid is plasma, replacement of deficient
blood components (for example, coagulation factors and
natural anticoagulants) [7]. Plasma exchange, however,
also has the potential to cause harm by diluting or at-
tenuating the host’s adaptive response to infection.
Case reports and small observational studies in humans
with septicemia or meningococcemia suggest a survival
benefit of plasma or whole blood exchange when com-
pared with expected survival rates [8-16]. While some
studies have reported a fourfold increase in survival com-
pared with historical controls [16], others have found rela-
tive survival benefits of 4 to 25% [13,15]. The small sample
size of these studies and the lack of a contemporaneous
comparator limit our ability to draw conclusions regarding
the risks and benefits of plasma exchange in sepsis and
septic shock. Currently, the American Society for Apher-
esis lists plasma exchange as an experimental treatment
for sepsis and multiorgan failure, and considerable prac-
tice variability exists in the application of apheresis tech-
nologies for the treatment of sepsis [6]. The objective of
this systematic review was to examine the efficacy and
safety of plasma exchange compared with usual care in pa-
tients with sepsis or septic shock.
Methods
Using an a priori published protocol (CRD 420130-
04290), we conducted our systematic review in accord-
ance with the Methodological Expectations of Cochrane
Intervention Reviews guidelines [17] and reported our
results as per the Preferred Reporting Items for System-
atic Reviews and Meta-analysis guidelines for systematic
review and meta-analysis [18]. A review team comprised
of experts from multiple fields (hematology, critical care,
research methodology and library sciences) formulated
the research question, reviewed the search strategy and
review methods, and provided input throughout the re-
view process.
Research question
Our primary research question was: ’In critically ill patients
with sepsis, severe sepsis, septic shock, or disseminatedintravascular coagulation due to infection, is plasma ex-
change, compared with usual care, associated with differ-
ences in mortality, ICU and hospital length of stay, and
central venous catheter-related complications?’ (Additional
file 1). We included trials that met the following criteria:
prospective randomized trials of human subjects; trials en-
rolling adults or children; at least 80% of patients diagnosed
with sepsis, severe sepsis, septic shock or disseminated
intravascular coagulation due to infection; and plasma ex-
change or plasma filtration (regardless of timing, number of
treatments, replacement fluid or frequency of administra-
tion) was compared with placebo or usual care. Conven-
tional dialysis or hemofiltration were not considered as
plasma exchange, because the modalities differ in terms of
plasma protein removal and replacement fluid. Our pri-
mary outcome was all-cause mortality reported at longest
follow-up. Secondary outcomes included ICU and hospital
lengths of stay, and safety outcomes included central ven-
ous catheter-related complications (infection, thrombosis)
or procedural related complications. Additional file 2 pre-
sents inclusion and exclusion criteria.
Search strategy and study selection
We searched the following electronic databases from incep-
tion to 28 April 2014: MEDLINE (PubMed), EMBASE
(Ovid), and CENTRAL (the Cochrane Library – Wiley).
The Cochrane Highly Sensitive Search Strategy was used as
a model for searching [19]. The original search strategy was
designed for MEDLINE with input from an information
specialist and then translated for other databases. The fol-
lowing search terms were used: ‘sepsis; shock, septic;
disseminated intravascular coagulation; thrombocytopenia;
plasma exchange; plasma filtration; and blood compo-
nent removal’ (Additional file 3). We performed for-
ward searches of included trials and relevant reviews in
Scopus to identify additional citations. To identify on-
going or planned trials, we searched the World Health
Organization’s International Clinical Trials Registry
Platform. In addition to electronic database searching,
we searched abstracts and conference proceedings for
the following societies from 2008 to 2012: American
Society of Hematology, European Hematology Associ-
ation, American Thoracic Society, International Sympo-
sium on Intensive Care and Emergency Medicine,
Society of Critical Care Medicine, European Society of
Intensive Care Medicine, and American Society for
Apheresis. Finally, we hand-searched the bibliographies of
relevant reviews and included trials for additional cita-
tions. Reference management was performed in EndNote™
(version X6; Thomson Reuters, Philadelphia, PA, USA).
Two reviewers (ER and BLH) independently reviewed the
title and abstract of each citation to determine whether a
study generally met the inclusion criteria. The full text of
all citations listed as ‘include’ or ‘unsure’ by either reviewer
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view. The full-text versions of potentially relevant citations
were then independently assessed to determine whether
the trial satisfied the inclusion and exclusion criteria. Dis-
crepancies between reviewers were resolved through con-
sensus in discussion with a third reviewer (RZ).
Data extraction and management
Two reviewers (ER and BLH) independently extracted data
from included trials using standardized and piloted data ex-
traction forms. Discrepancies between reviewers were re-
solved through consensus in discussion with a third reviewer
(RZ). We extracted data including trial demographics (au-
thor, year of publication, country, funding source, publication
status, duration of follow-up, number of centers involved, in-
clusion and exclusion criteria, and methodological quality
using the Cochrane Collaboration Risk of Bias tool) [20,21].
In addition, we extracted patient demographics (age, sex,
ICU admission diagnosis), Acute Physiology and Chronic
Health Evaluation II score [22] or other illness severity score,
number of patients requiring mechanical ventilation or vaso-
pressors at baseline, co-interventions in the ICU (antibiotic
use, vasopressors, ventilator, corticosteroids, renal replace-
ment therapy), details of the intervention (type of apheresis
procedure, number of treatments administered, volume ex-
changed, replacement fluid used) and details pertaining to
the primary, secondary, and safety outcomes. Data manage-
ment was performed using Microsoft Excel 2011 (Microsoft
Excel for Mac 2011. Microsoft Corp. Redmond, WA, USA).
Quality assessment
We used the Cochrane Collaboration Risk of Bias tool to
assess the internal validity of included trials [20,21]. This
tool consists of six domains (sequence generation, allo-
cation concealment, blinding, incomplete outcome data,
selective outcome reporting, and other sources of bias)
and a categorization of the overall risk of bias. Each sep-
arate domain is rated low risk, unclear risk, or high risk.
If one or more individual domains were assessed as hav-
ing a high risk of bias, the overall score was rated as
having a high risk of bias. The overall risk of bias was
considered low only if all components were rated as hav-
ing a low risk of bias.
Data analysis
We analyzed data from the included trials using Cochrane
Review Manager (RevMan version 5.1, 2011; The Cochrane
Collaboration, Copenhagen, Denmark). For dichotomous
data, we expressed summary measures of effect as risk ra-
tios (RRs) with 95% confidence intervals (CIs) using the
Mantel–Haenszel method. We used a random-effects
model for all analyses. A RR of less than 1 suggests a lower
rate of death among patients treated with plasma exchange
than those in the control group. We assessed statisticalheterogeneity of the data using the I2 statistic. We investi-
gated potential sources of heterogeneity using subgroup
analyses based on methodological characteristics, quality
and patient characteristics. Due to the small number of in-
cluded trials, systematic evaluation of publication bias was
not possible.
Subgroup analyses
To investigate potential statistical heterogeneity, we per-
formed subgroup analyses in several prespecified groups,
including children versus adults and trials conducted in
North America versus in other continents.
Results
Of the 1,957 records identified from electronic and hand
searches, we included four unique randomized trials en-
rolling a total of 194 patients (Figure 1, Table 1) [23-26].
All were published in peer-reviewed, English-language
journals. All trials were at unclear to high risk of bias
(Table 2). One trial was conducted in North America
[25], while the other three were conducted in Europe
[24], Australia [23] or both [26]. Two were multicenter
trials [23,26]. One trial enrolled adults only [24], one
trial enrolled both adults and children [23] and two trials
enrolled children only [25,26]. The mean age of adult
patients ranged from 38 to 53 years (n = 128) and the
mean age of children ranged from 0.9 to 18 years (n =
66). The mean Acute Physiology and Chronic Health
Evaluation scores were 25.2 (APACHE II) [23] and 54.9
(APACHE III) [24] in the two trials reporting baseline se-
verity of illness. Details of the intervention varied consider-
ably among the included trials (Table 1). The interventions
ranged from a single plasma exchange treatment [24], to
34 to 36 hours of continuous plasma filtration [23,26], to
daily plasma exchanges for 14 days [25]. Co-interventions
were poorly reported, with two trials reporting the number
of patients requiring ventilator and vasopressor support
[24,26].
Primary outcomes and subgroup analyses
Mortality either at 14 days [23], at 28 days [24,26], or at
an undefined time interval [25] was reported in the in-
cluded trials. We pooled data from all four trials (n =
192) to generate a summary RR for mortality (Figure 2).
Plasma exchange was not associated with a significant
reduction in death from all causes (RR = 0.83, 95% CI =
0.45 to 1.52). The heterogeneity was moderate (I2 = 60%,
uncertainly interval 0 to 87%).
To investigate the statistical heterogeneity, we per-
formed subgroup analyses according to the age of the
study population. In the two trials enrolling adult pa-
tients, the RR of mortality associated with plasma ex-
change was 0.63 (95% CI = 0.42 to 0.96, I2 = 0%, n = 128).
In the pediatric population, the RR for death associated
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-analysis study flow diagram.
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I2 = 60%, n = 66) (Figure 2). Subgroup analyses according
to trial geography (for example, North American vs.
other) resulted in nonsignificant and unstable point esti-
mates (Additional file 4).
Secondary outcomes
None of the included trials reported data on ICU or hos-
pital lengths of stay. Similarly, no trials included data on
central venous catheter-related complications. Only one
trial reported adverse events associated with apheresis
[24]. In this trial, six episodes of transient hypotension
and one allergic reaction to fresh frozen plasma were re-
ported in 81 plasma exchange procedures.
Discussion
In this systematic review, we observed the overall RR for
mortality in patients with sepsis treated with plasma ex-
change to be 0.83 (95% CI = 0.45 to 1.5, I2 = 60%). In
adults, plasma exchange was associated with a significant
reduction in all-cause mortality. Hospital and ICU lengths
of stay and adverse events were insufficiently reported.
Clinical heterogeneity among included trials was moderate
and all trials were at unclear or high risk of bias.
The pathogenesis of sepsis involves systemic inflamma-
tion and upregulation of coagulation [27,28]. This responseis characterized by the production of excessive inflamma-
tory cytokines (including tumor necrosis factor alpha,
interleukin-6, and interleukin-1β) [29], activation of coagu-
lation and depletion of natural anticoagulants (antithrom-
bin, tissue factor pathway inhibitor and protein C) [30,31].
Phase III trials examining replacement of deficient nat-
ural anticoagulants [32-35], and specific cytokines or
circulating mediators [36-39] have shown inconsistent
results. Therapies targeting broader aspects of immune
homeostasis regulation of inflammation may be a more
promising approach [5,40]. The role of plasma exchange
has been well established in other conditions such as
thrombotic thrombocytopenia purpura, a thrombotic mi-
croangiopathy associated with severely depleted levels of
A Disintegrin-like and Metalloproteinase with Thrombos-
pondin type-1 Motifs 13 (ADAMTS-13) [5,41]. Recently,
ADAMTS-13 deficiency has been described in patients
with severe sepsis and systemic inflammatory response
syndrome, leading to an increased interest in the role of
plasma exchange as an adjunct in the treatment of sepsis
[25,42]. One included trial showed that ADAMTS-13
levels were significantly increased in patients randomized
to receive plasma exchange [25]. Only one other trial pro-
vided data on inflammatory biomarkers, and this study
showed significant decreases in plasma concentrations of
C-reactive protein, alpha-1 antitrypsin, haptoglobin, and

















Plasma filtration 2 PV during first 4 to
6 hours, 3 PV throughout



























(1:1 ratio)(APACHE III) (PF-0.5 [Lvov, Russia]
and DK2-03 [Rjazan, Russia]
plasmapheresis machine)
(Repeated once if no
clinical improvement)
Mean 1,820 ± 402 ml
(first session) and































NR Plasma filtration 2 PV over first 2 hours
(100 ml/kg) followed
by 6 PV over the next










APACHE, Acute Physiology and Chronic Health Evaluation; Ctrl, control; FFP, fresh frozen plasma; IQR, interquartile range; NR, not reported; P, plasmapheresis;
PELOD, Pediatric Logistic Organ Dysfunction; PV, plasma volume; SD, standard deviation. aResults inferred from published graph.
Rimmer et al. Critical Care  (2014) 18:699 Page 5 of 8complement fraction C3 in patients who were randomized
to plasma exchange [23].
Our meta-analysis builds upon a previously published
review of blood purification modalities (including hemofil-
tration, hemoperfusion, plasma exchange or dialysis) in
sepsis [43]. In that meta-analysis, authors restricted the
analysis to adults and thus incorporated data from only
two [23,24] of the four trials on plasma exchange included
in our review. The diversity of blood purification methods
included in the previous review is an additional limitation.
To increase the homogeneity of the study intervention
and generalizability of the meta-analysis, we included only
trials that studied plasma exchange as the intervention.
Our search identified an additional trial examining a
proprietary method of blood purification called coupled
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hemodialysis filter [44]. Plasma was not replaced. This
trial found that coupled plasma filtration absorption did
not reduce mortality in patients with septic shock but
the authors hypothesized that there may be a mortality
reduction when high volumes of plasma were processed.
We excluded this trial from the formal meta-analysis be-
cause the coupled plasma filtration absorption process in-
volves renal replacement therapy as part of the intervention,
which was an a priori exclusion criteria for our review.
The strengths of our systematic review are the compre-
hensive search strategy, which included multiple electronic
database searches, hand searching of grey literature and
bibliographies of included trials and forward searching.
We used an a priori published protocol and followed the
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Figure 2 Mortality associated with plasma exchange. Boxes and horizontal lines represent point estimates, varying in size according to the
weight in the analysis, and 95% confidence intervals. Chi2 = Chi-squared; df = degrees of freedom; CI = Confidence interval; I2 = I-squared;
M-H = Mantel-Haenszel; P = P value; RR = risk ratio; Tau2 = Tau-squared; Z = Z score.
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bias of our included trials, which facilitated data interpret-
ation in the context of trial methodology. Finally, we
explored potential sources of clinical and statistical hetero-
geneity with a priori defined subgroup analyses.
There are several limitations of this systematic review
that relate to the primary data. First, the small number
of trials and patients enrolled is an important limitation
of the data. Second, there were substantial baseline im-
balances to consider in several of the included trials.
Baseline differences such as younger age [23] and fewer
patients requiring mechanical ventilation [24] in the
intervention group may have biased the results of those
included trials in favor of plasma exchange. In addition,
one trial had higher illness severity scores in the plasma
exchange group, which would have biased the mortality
estimate in favor of the null hypothesis [26]. Technical
differences in the application of plasma exchange existed
among the included trials. The optimal plasma separ-
ation method, dose, and type of replacement therapy re-
main uncertain. These procedural details must be
considered when deciding upon specific apheresis inter-
ventions (for example, dose, frequency, replacement
fluid, duration of study, and so forth) in future trials.
Although all trials reported objective patient-oriented
outcomes such as mortality, the duration of follow-up in
these trials is short (14 or 28 days) and represents a fur-
ther limitation of these data because follow-up of 90 days
may be required to capture the full impact of interventions
on longer term vital status in patients with sepsis [45].
An additional notable limitation is that only one trial
reported adverse effects related to plasma exchange [24].No trials addressed central venous catheter-related com-
plications. Although thought to be a safe procedure,
plasma exchange can be associated with cardiovascular
instability, allergic reaction, or infection and/or throm-
bosis related to the presence of a large-bore central ven-
ous catheter [46,47].
Conclusions
Insufficient evidence exists to recommend plasma exchange
as an adjunctive therapy for patients with sepsis or septic
shock. Rigorous randomized controlled trials evaluating
clinically relevant patient-centered outcomes are required to
evaluate the impact of plasma exchange in this condition.
Key messages
 Sepsis and septic shock are leading causes of
mortality in critically ill patients.
 Plasma exchange was not associated with a
significant reduction in all-cause mortality overall,
but was associated with a reduction in mortality in a
subgroup of adult patients.
 Rigorous randomized controlled trials are required
to evaluate the impact of plasma exchange in sepsis
and septic shock.Additional files
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